Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of dexmedetomidine and salbutamol appears to be a treatment approach that has been studied for acute asthma management. According to the search results, this combination has been evaluated in clinical trials, particularly for its potential efficacy in treating acute asthma exacerbations in emergency department settings[1][9].\n\n## Drug Information\n\nDexmedetomidine is a selective α2-adrenoreceptor agonist that has sedative, analgesic, anti-inflammatory, and sympatholytic properties[7]. It's primarily used for sedation in intensive care settings and during procedures[3][10]. Salbutamol (also known as albuterol in the US) is a moderately selective beta-2 receptor agonist widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases[5][6].\n\n## Clinical Evidence\n\nA clinical trial published in 2021 evaluated the efficacy of using dexmedetomidine with salbutamol compared to salbutamol nebulization alone in patients with acute exacerbation of asthma presenting to the emergency department[1]. The study included 60 patients aged 18-55 years with signs of bronchospasm. In the intervention group, dexmedetomidine 0.5 μg/kg was injected intravenously along with three doses of salbutamol nebulization administered over 60 minutes, while the control group received only salbutamol nebulization three times over 60 minutes[1].\n\nThe results showed that the increased mean forced expiratory volume in 1 second and mean peak expiratory flow rate were similar in both groups during treatment, indicating no significant difference in efficacy. However, the mean systolic and diastolic blood pressure recorded at 40 and 60 minutes were significantly lower in the dexmedetomidine group[1].\n\nThe study concluded that the administration of dexmedetomidine in addition to standard salbutamol treatment had no beneficial effect in patients with acute asthma attacks and merely caused hypotension in patients[1].\n\n## Pediatric Use\n\nThere is also mention of dexmedetomidine with continuous salbutamol inhalation being used in the treatment of pediatric near-fatal asthma, though detailed information on this application is limited in the search results[2][4].\n\n## Drug Interactions\n\nThe search results indicate that dexmedetomidine and salbutamol may have some interaction effects. Specifically, the risk or severity of hypertension can be increased when dexmedetomidine is combined with salbutamol[3][5]. This interaction should be considered when administering these medications together.\n\n## Safety Considerations\n\nWhen using dexmedetomidine with salbutamol, healthcare providers should be aware of potential cardiovascular effects. The clinical trial mentioned above found that the combination caused hypotension in patients[1]. Additionally, dexmedetomidine may decrease the excretion rate of other drugs, potentially resulting in higher serum levels[3].\n\nIn summary, while the combination of dexmedetomidine and salbutamol has been studied for acute asthma management, current evidence suggests it may not provide additional benefits over salbutamol alone and may increase the risk of hypotension and other cardiovascular effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dexmedetomidine and Salbutamol Combination.